Enliven Therapeutics, Inc (ELVN) insider trading
Every open-market stock purchase and sale by Enliven Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Mika K Derynck (Insider) and 3 others sold $11.8M in the last 90 days.
- Last insider buy: Commodore Capital LP (10% owner), $13.7K, 3 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $76.5M (35 sales). Last close $46.09 on Sep 23, 2026.
Recent ELVN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Sep 17, 2026 | Benjamin Hohl (CFO) | Sold | $177K |
| Sep 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $146K |
| Sep 17, 2026 | Benjamin Hohl (CFO) | Sold | $111K |
| Sep 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $93.5K |
| Sep 17, 2026 | Benjamin Hohl (CFO) | Sold | $14.9K |
| Sep 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $12.4K |
| Sep 17, 2026 | Benjamin Hohl (CFO) | Bought (not open market) | — |
| Sep 17, 2026 | Helen Louise Collins (C-suite exec) | Bought (not open market) | — |
| Aug 17, 2026 | Benjamin Hohl (CFO) | Sold | $270K |
| Aug 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $228K |
| Aug 17, 2026 | Benjamin Hohl (CFO) | Sold | $82.4K |
| Aug 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $65.3K |
| Aug 17, 2026 | Helen Louise Collins (C-suite exec) | Bought (not open market) | — |
| Aug 4, 2026 | Mika K Derynck (Insider) | Sold | $9.6M |
| Aug 4, 2026 | Mika K Derynck (Insider) | Bought (not open market) | — |
| Aug 4, 2026 | Mika K Derynck (Insider) | Bought (not open market) | — |
| Aug 4, 2026 | Mika K Derynck (Insider) | Bought (not open market) | — |
| Aug 4, 2026 | Mika K Derynck (Insider) | Bought (not open market) | — |
| Jul 17, 2026 | Benjamin Hohl (CFO) | Sold | $141K |
| Jul 17, 2026 | Benjamin Hohl (CFO) | Sold | $134K |
| Jul 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $117K |
| Jul 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $108K |
| Jul 17, 2026 | Helen Louise Collins (C-suite exec) | Sold | $23.7K |
| Jul 17, 2026 | Benjamin Hohl (CFO) | Sold | $19K |
| Jul 17, 2026 | Benjamin Hohl (CFO) | Sold | $16.2K |
Who's trading ELVN
- Helen Louise Collins, C-suite exec: sold $5.4M (24 sales), last Sep 17, 2026
- Benjamin Hohl, CFO: sold $1.5M (14 sales), last Sep 17, 2026
- Mika K Derynck, Insider: sold $9.6M (1 sale), last Aug 4, 2026
- Lori Anne Kunkel, Insider: sold $850K (5 sales), last Jul 6, 2026
- Orbimed Advisors LLC, 10% owner: sold $51.7M (6 sales), last Jun 22, 2026
- Richard A. Heyman, Insider: sold $413K (6 sales), last Feb 17, 2026
- Rishi Gupta, Insider: other filings, last Feb 12, 2026
- Rahul D. Ballal, Insider: other filings, last Feb 12, 2026
- Jake Bauer, Insider: other filings, last Feb 12, 2026
- J. Scott Garland, Insider: other filings, last Feb 12, 2026
- Anish Patel, COO: sold $1.7M (7 sales), last Feb 12, 2026
- Joseph P Lyssikatos, C-suite exec: sold $4.8M (11 sales), last Feb 12, 2026
- Richard A. Fair, CEO: other filings, last Dec 11, 2025
- Samuel Kintz, CEO: sold $539K (2 sales), last Nov 17, 2025
Get free alerts when an insider at Enliven Therapeutics, Inc files a new trade →